CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 542 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CLK1/2-IN-3
CAS:CLK1/2-IN-3 (Cpd-3) is a CLK1 and CLK2 inhibitor with antiproliferative activity that inhibits the activity of CLK and SRPK.Fórmula:C21H21N5O2Pureza:99.04%Cor e Forma:SolidPeso molecular:375.42ARN22089
CAS:ARN22089 is an oral active CDC42 GTPase interaction inhibitor that blocks tumour growth in BRAF mutant mouse melanoma models and PDXs in vivo.Fórmula:C23H27N5Pureza:98.37%Cor e Forma:SolidPeso molecular:373.49Ref: TM-T85727
1mg109,00€5mg260,00€10mg385,00€25mg647,00€50mg964,00€100mg1.431,00€200mg1.963,00€1mL*10mM (DMSO)286,00€CDK12-IN-E9
CAS:CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux.Fórmula:C24H30N6O2Cor e Forma:SolidPeso molecular:434.53AS2863619 free base
CAS:AS2863619 free base enables the conversion of antigen-specific effector/memory T cells into Foxp3+ regulatory T (Treg) cells.Fórmula:C16H12N8OCor e Forma:SolidPeso molecular:332.32CLK1-IN-1
CAS:CLK1-IN-1 is a potent and selective inhibitor of the Cdc2-like kinase 1 (CLK1; IC50: 2 nM).Fórmula:C24H16FN5OCor e Forma:SolidPeso molecular:409.42THZ1-R
CAS:THZ1-R is a non-covalent active analogue of THZ1, with the acrylamide group removed from THZ1, not covalently bind to the C312 cysteine residue of CDK7.Fórmula:C31H30ClN7O2Pureza:98%Cor e Forma:SolidPeso molecular:568.07NSC 625987
CAS:NSC 625987, Selective CDK4 inhibitor (IC50=0.2 μM), >500-fold selectivity over CDK2, used for p16-associated tumor studies.Fórmula:C15H13NO2SPureza:98%Cor e Forma:SolidPeso molecular:271.33CDK8/19-IN-51
CAS:CDK8/19-IN-51 is a CDK8 and CDK19 inhibitor with anticancer activity, used in research on colorectal and gastric cancers.Fórmula:C23H22N6O2Pureza:98.65% - 99.62%Cor e Forma:SoildPeso molecular:414.46CDK2-IN-13
CAS:CDK2-IN-13: Potent CDK2 inhibitor, arrests cell cycle, induces apoptosis, IC50=12 µM, used in cancer research.Fórmula:C13H12ClN5Cor e Forma:SoildPeso molecular:273.72Cdc7-IN-5
CAS:Cdc7-IN-5: potent Cdc7 serine-threonine kinase inhibitor, critical for starting DNA replication.Fórmula:C25H23N3O5Pureza:98.4%Cor e Forma:SolidPeso molecular:445.47Ref: TM-T10727
1mg96,00€5mg227,00€10mg376,00€25mg620,00€50mg847,00€100mg1.169,00€1mL*10mM (DMSO)250,00€Cdc7-IN-13
CAS:Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].Fórmula:C18H20N4O2SCor e Forma:SolidPeso molecular:356.44Ulecaciclib
CAS:Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).Fórmula:C25H33FN8SCor e Forma:SolidPeso molecular:496.65CDK4/6-IN-9
CAS:CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.Fórmula:C22H23FN8Cor e Forma:SolidPeso molecular:418.47CDK1-IN-1
CAS:CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.Fórmula:C27H23N5O3Cor e Forma:SolidPeso molecular:465.5Indirubin-5-sulfonate
CAS:Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.Fórmula:C16H10N2O5SPureza:98%Cor e Forma:SolidPeso molecular:342.33CDK7-IN-8
CAS:CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.Fórmula:C25H38N8O3Cor e Forma:SolidPeso molecular:498.62JTK-101
CAS:JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.Fórmula:C25H23N3O3Cor e Forma:SolidPeso molecular:413.47Cdc7-IN-3
CAS:Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.Fórmula:C20H22N4O5Pureza:98%Cor e Forma:SolidPeso molecular:398.41FN-1501-propionic acid
CAS:FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.Fórmula:C25H27N9O4Pureza:98%Cor e Forma:SolidPeso molecular:517.54FLT3/CDK4-IN-1
CAS:FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.Fórmula:C25H28F2N8Cor e Forma:SolidPeso molecular:478.54
